medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2007, Número 4

<< Anterior Siguiente >>

Acta Med 2007; 5 (4)


Tratamiento endovascular de la Enfermedad Arterial Oclusiva Periférica (EAPO) del sector infrainguinal

Águila MR, Marquina RM

Idioma: Español
Referencias bibliográficas: 43
Paginas: 197-208
Archivo PDF: 788.09 Kb.


RESUMEN

La terapia endovascular hoy en día es una alternativa confiable y segura para resolver la enfermedad arterial periférica oclusiva, especialmente en el sector infrainguinal. Avances en los procedimientos incluyen: balones de angioplastia cortantes, crioplastia, el uso de endarterotomo motorizado en placas concéntricas, así como la utilización de láser para vasos tibiales infrageniculares. Estos avances son una realidad y especialmente útiles en aquellos pacientes con alto riesgo quirúrgico. Actualmente el éxito técnico de una revascularización por medios endovasculares en pacientes claudicadores en el sector femoropoplíteo excede el 95%, presentan una morbi-mortalidad que no rebasa el 3%. Este artículo tiene como finalidad dar a conocer los nuevos métodos y técnicas con las que cuenta un cirujano vascular para resolver la patología arterial periférica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter–Society Consensus (TASC). J Vasc Surg 2000; 31(1 Pt 2): S1–296.

  2. Cheng SW, Ting AC, Ho P. Angioplasty and primary stenting of high–grade, long–segment superficial femoral artery disease: is it worthwhile? Ann Vasc Surg 2003; 17: 430-437.

  3. Surowiec SM, Davies MG, Eberly SW et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg 2005; 41: 269-278.

  4. Gray BH, Sullivan TM, Childs MB et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long–segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 1997; 25: 74-83.

  5. Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 2006; 13(Suppl 2): II30-1140.

  6. Lyden SP, Shimshak TM. Contemporary endovascular treatment for disease of the superficial femoral and popliteal arteries: an integrated device–based strategy. J Endovasc Ther 2006; 13(Suppl 2): II41-1151.

  7. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-944.

  8. Kandarpa K, Becker GJ, Hunink MG et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001; 12: 683-695.

  9. Mewissen MW. Self–expanding nitinol stents in the femoropopliteal segment: technique and mid–term results. Tech Vasc Interv Radiol 2004; 7: 2-5.

  10. Schlager O, Dick P, Sabeti S et al. Long–segment SFA stenting–the dark sides: in–stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther 2005; 12: 676-684.

  11. Arena FJ. Arterial kink and damage in normal segments of the superficial femoral and popliteal arteries abutting nitinol stents–a common cause of late occlusion and restenosis? A single–center experience. J Invasive Cardiol 2005; 17: 482-486.

  12. Scheinert D, Scheinert S, Sax J et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312-315.

  13. Rabin Y, Taylor MJ, Wolmark N. Thermal expansion measurements of frozen biological tissues at cryogenic temperatures. J Biomech Eng 1998; 120: 259-266.

  14. Isner JM, Kearney M, Bortman S et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703-2711.

  15. Fava M, Loyola S, Polydorou A et al. Cryoplasty for femoropopliteal arterial disease: late angiographic results of initial human experience. J Vasc Interv Radiol 2004; 15: 1239-1243.

  16. Laird JR, Biamino G, McNamara T et al. Cryoplasty for the treatment of femoropopliteal arterial disease: extended follow–up results. J Endovasc Ther 2006; 13(Suppl 2): II52-1159.

  17. Allie D, Berens E, Ramaiah V et al. Plaque excision in the peripheral vasculature. Endovasc. Today 2004; (Suppl2): II 3-11.

  18. Shafique S, Nachreyner R et al. Recanalization of infrainguinal vessels: Silverhawk, laser, and the remote superficial femoral artery endarterectomy. Sem Vasc Surg 2007; 20: 29-36.

  19. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol 2004; 7: 2-5.

  20. Ascher E, Marks NA, Hingorani AP. Duplex guided balloon angioplasty and subintimal dissection of infrapopliteal arteries: early results with new approach to avoid radiation exposure and contrast material. J Vasc Surg 2005; 42: 1114-1121.

  21. Mossop P, Cincotta M, Whitbourn R. First case reports of controlled blunt microdissection for percutaneous transluminal angioplasty of chronic total occlusions in peripheral arteries. Catheter Cardiovasc Interv 2003; 59: 255-258.

  22. Yang YM, Mehran R, Dangas G et al: Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. Catheter Cardiovasc Interv 2004; 63: 462-468.

  23. Wissgott C, Scheinert D, Rademaker J, Werk M, Schedel H, Steinkamp HJ. Treatment of long superficial femoral artery occlusions with excimerlaser angioplasty: long-term results after 48 months. Acta Radiol 2004; 45: 23-29.

  24. Scheinert D, Laird JR Jr, Schroder M, Steinkamp H, Balzer JO, Biamino G. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. J Endovasc Ther 2001; 8: 156-166.

  25. Steinkamp HJ, Wissgott C, Rademaker J et al: Short (1-10 cm) superficial femoral artery occlusions: results of treatment with excimer laser angioplasty. Cardiovasc Intervent Radiol 2002; 25: 388-396.

  26. Lagerquist et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 10-1009-1019.

  27. Mauri et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 10-1020-27.

  28. Gale TL et al. Role of stents, drug-eluting stents, and stent-grafts in treatment of infrainguinal arterial disease. Sem Vasc Surg 2007; 20,1: 37-41.

  29. Popma JJ. Long-term safety and efficacy of drug-eluting stents: Two-year results of the REAL (REgistro AngiopLastiche dell’Emilia Romagna) Multicenter Registry. American Heart Association. Circulation 2007; 115(25): 3181-3188.

  30. Becquemin J-P, Favre J-P, Marzelle J. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg 2003; 37: 487-494.

  31. Duda SH, Bosiers M, Lammer J et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005; 16: 331-338.

  32. Fischer M, Schwabe C, Schulte K-L. Value of the Hemobahn/Viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J Endovasc Ther 2006; 13: 281-290.

  33. Regar E, Serruys P, Bode C et al. Angiographic findings of the multi-center randomized study with the sirolimus-eluting Bx velocity balloon-expandable stent (RAVEL): sirolimus-eluting stent inhibit restenosis irrespective of the vessel size. Circulation 2002; 106: 1949-1956.

  34. Holmes D, Leon M, Moses J et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-640.

  35. Schampaert E, Cohen E, Schluter M et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004: 43: 1110-1115.

  36. Lemos P, Lee C, Degertekin M et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003; 41: 2093-2099.

  37. Grube E, Silber S, Hauptmann K et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.

  38. Serruys P, Degertekin M, Tanabe K et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stent: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004; 109: 627-633.

  39. Tanabe K, Serruys P, Grube E et al. TAXUS III trial: in-stent re stenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-564.

  40. Stone G, Ellis S, Cox D et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-1947.

  41. Goy J, Stauffer J, Siegenthaler M et al. A prospective randomized comparison between paclitaxel and sirolimus stent in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005; 45: 308-311.

  42. Meredith I, Ormiston J, Whitbourn R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. Eurointervention 2005; 1: 157-164.

  43. Tsuchida K, Piek J, Neumann FJ et al. One-year results of a durable polymer everolimus-eluting stents in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointervention 2006). in press.




2020     |     www.medigraphic.com